公开(公告)号：US20220160747A1

公开(公告)日：2022-05-26

申请号：US17440877

申请日：2020-03-20

Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

Inventor： Seong Jun PARK ,  Chang Hoon LEE ,  Hwan Jung LIM

IPC: A61K31/7076 ,  A61K31/52 ,  A61P35/00

Abstract: The present invention relates to a pharmaceutical composition for the prophylaxis or treatment of cancer comprising a novel azolopyrimidine heterocyclic compound as an active ingredient, and the pharmaceutical composition for the prophylaxis or treatment of cancer of the present invention can be used as a small molecular immunotherapy anticancer agent which modulates an adenosine pathway by comprising the azolopyrimidine heterocyclic compound.

公开(公告)号：US20200087286A1

公开(公告)日：2020-03-19

申请号：US16610327

申请日：2018-05-02

Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

Inventor： Sung Yun CHO ,  Chang Hoon LEE ,  Yong Ki MIN ,  Jong Yeon HWANG

IPC: C07D403/14 ,  C07D239/48 ,  C07D403/04 ,  C07D413/14 ,  C07D405/04 ,  C07D409/14 ,  C07D417/14 ,  C07D405/14

Abstract: The present invention relates to a pyrimidine derivative compound, an optical isomer thereof, or a pharmaceutically acceptable salt thereof, and a composition for preventing or treating cancer comprising the same as an active ingredient. The pyrimidine derivative compound, the optical isomer thereof, or the pharmaceutically acceptable salt thereof according to the present invention has an excellent selective inhibitory effect especially against TYRO 3 among TAM receptor inhibitory effects, and thus can be used as an excellent composition of preventing or treating cancer without adverse effects resulting from the inhibition of Axl and Mer.

公开(公告)号：US20220017491A1

公开(公告)日：2022-01-20

申请号：US17292699

申请日：2019-11-08

Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY ,  INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY

Inventor： Hwan Jung LIM ,  Seong Jun PARK ,  Chang Hoon LEE ,  Kyoung Tai NO ,  Jiwon CHOI ,  Hei-Cheul JEUNG ,  You-keun SHIN ,  Jong Wan KIM ,  Xuemei JIN

IPC: C07D401/14 ,  C07D401/12 ,  C07D409/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D513/04

Abstract: The present invention relates to a compound which inhibits the binding of Yes associated protein (YAP) and transcriptional enhancer associate domain (TEAD), a prodrug of same, a hydrate of same, a solvate of same or a pharmaceutically acceptable salt of same, and a composition comprising same as an active ingredient, the compound according to the present invention being able to be applied as an inhibitor which can directly inhibit YAP-TEAD binding in the Hippo pathway which plays a crucial role in the occurrence of cancer.